lerapolturev
istari
['luminos-102', 'melanoma']
we are thrilled to share response data from our ongoing phase 2 trial of lerapolturev in anti-pd-1 relapsed/refractory metastatic melanoma (luminos-102) being presented this week at the society for melanoma research ltd research (smr) 2022 congress!
Istari Oncology is a clinical-stage biotechnology company developing novel immunotherapies for the treatment of solid tumors.